What Cats Are Teaching Us About Cancer

A landmark study just mapped the feline oncogenome. The findings could change how you treat cancer in cats and open doors for human patients too.

For decades, the cat has been the overlooked patient in comparative oncology. Dogs got the research dollars. Humans got the clinical trials. Cats got managed, palliatively, with tools borrowed from other species and hope borrowed from wherever you could find it.

That is starting to change. And a study published this month in Science is one of the most significant reasons why.

Researchers performed targeted sequencing of 493 feline tumor-normal tissue pairs across 13 tumor types, assessing the mutational status of 978 feline orthologs of approximately 1,039 human cancer genes. The result is the most comprehensive characterization of the feline oncogenome ever produced. And what they found should matter to every veterinary professional who sees feline cancer cases — which is to say, all of you.

The Feline Oncogenome Looks Familiar

The headline finding is this: the feline oncogenome has multiple significant similarities to the human oncogenome. Shared recurrent mutations were identified in TP53, FBXW7, and CTNNB1 — genes that human oncologists have been studying and targeting for years. Five genes emerged as drivers across multiple tumor types: TP53, CTNNB1, PTEN, TRAF3, and FBXW7. The most recurrently mutated gene was TP53, with 14 mutation hotspots identified across 10 genes.

This matters clinically because it means the wall between feline and human oncology research is thinner than the field has historically treated it. Cats are not just patients. They are a naturally occurring comparative model for human cancer biology, living in the same environments, exposed to the same carcinogens, and apparently sharing enough of the same genetic drivers to make cross-species translation a legitimate scientific conversation.

The Tumor Types You Need to Know About

The 13 tumor types studied included some of the most common presentations in feline practice. The most frequently represented were cutaneous squamous cell carcinoma, lung adenocarcinoma, lymphoma, and mammary carcinoma. If you are seeing cats regularly, you are seeing these cases.

Mammary carcinoma stood out in the copy-number alteration data, showing the highest mean genome fraction altered of any tumor type studied. PIK3CA p.H1047R, the most frequently observed mutation hotspot overall, occurred in 30% of mammary carcinoma cases. Colorectal adenocarcinoma, by contrast, showed the fewest copy-number alterations of any tumor type.

T-cell lymphoma showed striking MYC copy-number gain at 57% — compared to 20% across all tumors — a finding that opens questions about targeted therapeutic approaches for a cancer type that remains challenging to manage.

The Actionability Question

Here is where it gets clinically interesting for everyday practice. The researchers found that 14% of feline tumors carried an oncogenic or likely oncogenic mutation in at least one actionable driver gene. Those genes include PIK3CA, MAP2K1, KIT, FBXW7, FGFR2, PTEN, and NF1.

KIT as a driver in cutaneous mast cell tumor will not surprise experienced clinicians. But the breadth of actionable mutations across tumor types points toward a future in which targeted sequencing becomes a meaningful part of feline oncology workups — not just for academic interest, but because the results could directly inform treatment decisions.

The researchers also found that FBXW7 mutant lines showed significantly greater sensitivity to the vinca alkaloids vincristine and vinorelbine, consistent with prior in vitro findings in human cells. That is a result that recommends further investigation in larger cohorts and represents exactly the kind of cross-species clinical translation this study was designed to enable.

The Viral Angle

The study also examined viral etiology, given that feline leukemia virus, feline immunodeficiency virus, and papillomavirus all carry oncogenic potential in cats. Researchers identified strong evidence of two genera of papillomavirus — Dyothetapapillomavirus and Taupapillomavirus — in cutaneous squamous cell carcinoma and basal cell carcinoma samples. For clinicians managing these presentations, the viral connection is worth keeping in the differential conversation.

Why This Study Is a Turning Point

Study co-author Sven Rottenberg, PhD, of the University of Bern put it plainly: having access to 493 donated tissue samples allowed the research team to assess drug responses across tumor types at a scale that has not been possible before in feline oncology. That scale is what makes this a foundational study rather than an incremental one.

The feline oncogenome now has a map. It is not complete. But it is detailed enough to start navigating by.

For veterinary professionals, the immediate takeaway is not that everything about how you manage feline cancer changes today. It is that the scientific infrastructure for better feline oncology is being built right now, with your patients at the center of it. The cat, it turns out, has been one of the most important comparative oncology models available all along. The profession is finally catching up to that reality.

The research was supported by the EveryCat Health Foundation, a CVS (UK) Limited Flexible Clinical Research Award, the Wellcome Trust, the Natural Sciences and Engineering Research Council of Canada, and the Swiss National Science Foundation.

The full study is published in Science.